Jun 25 |
Why Oragenics (OGEN) Shares Are Falling
|
Jun 20 |
Oragenics announces NYSE American acceptance of plan of compliance
|
Jun 20 |
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
|
May 22 |
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
|
May 17 |
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
|
May 16 |
Oragenics climbs 9% amid Phase 2 study, business updates
|
May 16 |
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
|
May 7 |
Oragenics partners with Avance Clinical for Phase 2 concussion study
|
May 7 |
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
|
Mar 18 |
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
|